EuroEyes International Eye Clinic (HKG:1846) Full Year 2024 Results
Key Financial Results
- Revenue: HK$715.7m (flat on FY 2023).
- Net income: HK$82.3m (down 37% from FY 2023).
- Profit margin: 12% (down from 18% in FY 2023).
- EPS: HK$0.25 (down from HK$0.40 in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
EuroEyes International Eye Clinic Revenues and Earnings Miss Expectations
Revenue missed analyst estimates by 3.9%. Earnings per share (EPS) also missed analyst estimates by 11%.
The primary driver behind last 12 months revenue was the Germany segment contributing a total revenue of HK$396.0m (55% of total revenue). Notably, cost of sales worth HK$429.1m amounted to 60% of total revenue thereby underscoring the impact on earnings. The largest operating expense was General & Administrative costs, amounting to HK$116.0m (57% of total expenses). Explore how 1846's revenue and expenses shape its earnings.
The company's shares are up 1.4% from a week ago.
Risk Analysis
It's still necessary to consider the ever-present spectre of investment risk. We've identified 2 warning signs with EuroEyes International Eye Clinic, and understanding these should be part of your investment process.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.